1.1Slow release from the wall
A hollow polymer nanocapsule holds the slow-release fraction within its solid wall and water in its central cavity. Water enters the wall, and the dissolved compound diffuses outward through the polymer.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A hollow polymer nanocapsule holds the slow-release fraction within its solid wall and water in its central cavity. Water enters the wall, and the dissolved compound diffuses outward through the polymer.
A capsule contains a powder that disperses into nanoparticles and a second fraction made of coated granules. Water penetrates the ethylcellulose coating on the granules, and dissolved compound diffuses through water-filled pores.
Each unit contains nanoparticles with a water-soluble core that dissolves on contact with fluid. The units are administered at preset intervals, and each administration supplies a separate pulse.
An uncoated porous polymer particle holds readily soluble material as deposits on the walls of open pores. Fluid enters the pores directly and dissolves those deposits, while compound embedded in the polymer matrix diffuses out more slowly.
A capsule contains controlled-release nanoparticles and separate water-soluble granules containing the rapid-release fraction. The capsule opens in fluid, which dissolves the granules while release from the nanoparticles continues.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A mesoporous silica core holds benzotriazole in its pores, and a water-soluble polyvinyl alcohol shell contains sodium benzoate. The particles are dispersed in a solventborne acrylic primer applied to steel. Water entering a coating defect dissolves the shell and releases sodium benzoate, while benzotriazole diffuses out of the wetted pores over a longer interval.
Mesoporous silica serves as the controlled-release core in place of a polymer matrix. Riboflavin is loaded by soaking the silica in an aqueous solution and drying it, and a thin mannitol shell containing riboflavin is deposited by spray drying. On rehydration, the mannitol dissolves and releases its riboflavin first, while riboflavin held inside the silica pores diffuses into the surrounding liquid.
A porous silica core holds fragrance oil, and a brittle cross-linked acrylic shell contains a second portion of the same oil in dispersed droplets. The particles are incorporated into a waterborne coating and dried on paper. Rubbing the surface fractures the shell and exposes its droplets for immediate evaporation, while oil in the exposed core pores diffuses out and evaporates more slowly.
Each particle has a 240 nm ethylcellulose core containing caffeine and a water-soluble shell of polyvinyl alcohol and caffeine. Two batches use nominal dry shell thicknesses of 10 nm and 25 nm, giving outer diameters of 260 nm and 290 nm. Both batches use the same shell composition, and the thicker shell supplies more caffeine per particle during initial dissolution. The ethylcellulose core then releases its caffeine by diffusion.
Lipid cores containing caffeine are coated with a water-soluble shell containing caffeine and mannitol. The dry particles are dispersed in an ethanol-based hydroxypropyl cellulose casting solution and incorporated into an oral film by solvent evaporation. Saliva dissolves the film and the particle shells, releasing the shell dose and dispersing the lipid cores. The cores continue to release caffeine into the surrounding fluid.
A continuous mixer forms ethylcellulose cores containing caffeine, and a downstream spray dryer applies a water-soluble shell containing a second portion of caffeine. An automated flow-through dissolution sampler measures caffeine released at one minute and sixty minutes using liquid chromatography. A controller adjusts the shell-solids feed for subsequent material using the one-minute result and flags material whose sixty-minute release falls outside the specified range.
A polyethylene glycol layer stabilizes the nanoparticle surface during dispersion. A soluble fraction of the compound sits in the tablet matrix, and a swelling disintegrant breaks the tablet apart to expose that fraction to fluid.
A poly(lactide-co-glycolide) core contains the compound dispersed through a solid polyester matrix. Water enters the core, and diffusion and polymer hydrolysis govern release.
A glyceryl behenate core contains the compound within a solid lipid matrix. The compound partitions into surrounding fluid as it diffuses through the matrix.
A dry polyvinylpyrrolidone shell contains a soluble fraction of the compound. On contact with fluid, the polymer dissolves and releases that fraction.
An amorphous trehalose shell contains the compound dispersed in a dry sugar glass. Fluid dissolves the shell and carries the compound into the surrounding liquid.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
In one embodiment, the dosage form comprises an immediate release portion and an enteric coated sustained release core, wherein the sustained release core is in the form of a matrix controlled release device and the immediate release portion is in the form of an immediate release coating.A · US 2008/0299188 A1 · ¶ 157
An immediate release coating 16 comprising the drug and optional excipients, as discussed above surrounds the enteric coating 14.A · US 2008/0299188 A1 · ¶ 157
In one embodiment, a pH agent (either an acid or base or neutral agent) together with a rapidly dissolving polymer is coated on the exterior of the dosage form. The polymer dissolves promptly when wetted by saliva and rapidly releases the pH agent and thereby rapidly modulates the pH of the saliva.B · US 2014/0065216 A1 · ¶ 10
An empty cell means only that no passage was reproduced there.
Accordingly, there is a continuing need for a controlled release oral dosage form that provides effective concentration of drug in the blood for relatively long periods of time for low-solubility drugs that are poorly absorbed over at least a portion of the gastrointestinal tract and that have a relatively short biological half life.A · US 2008/0299188 A1 · ¶ 4
The primary goal of a controlled release dosage form is to maintain the desired therapeutic effect for an extended period of time.A · US 2008/0299188 A1 · ¶ 2
The rapid release coating contains a material having a property of rapidly modulating a pH of bodily fluids in which the material comes in contact in a direction towards a pH which is most suitable for absorption considering the pKa of the at least one bioactive agent or alternatively towards a pH which is most suitable for retardation of absorption.B · US 2014/0065216 A1 · ¶ 3
This methodology would apply to all solid dosage units including without limitation capsules, liquigels, tablets, thin film, sheet, orally dissolving tablets, vaginal rings, suppositories, pessaries, topicals, microparticles, particles and the like.B · US 2014/0065216 A1 · ¶ 6
patent.fyi, US 2026/0355224 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355224/, SHA-256 636e9f2bdcdcce9b0508bc5b843f26affde1b0662adc7a7c52204c67077ce907